Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-89~* Diagnosis of indolent or intermediate grade B-cell malignancy~* Patients receiving rituximab-based therapy at a dose of 375mg/m2, regardless of weight~* First dose given within 3 months of the second dose~* Infusion scheduled for outpatient administration at The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute~Exclusion Criteria:~* Diagnosis of aggressive lymphoma~* Absolute lymphocyte count \> 10 x 103 cells/µL~* New York Heart Association (NYHA) classification Grade II or greater congestive heart failure~* Enrolled on another clinical trial~* Allergy to murine-containing medications~* Grade III or IV hypersensitivity reaction during the initial infusion of rituximab~* Prisoners~* Pregnant women~* Mentally or physically unable to give consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).